Stockwinners Market Radar for May 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:05 EDT Innoviva trading resumes

18:42 EDT Rocket Lab to acquire production and manufacturing assets from Virgin Orbit - Rocket Lab USA announced it has been selected as a successful bidder and is finalizing an asset purchase agreement for the purchase of certain Long Beach California aerospace production and manufacturing assets from Virgin Orbit Holdings and certain of its subsidiaries in Virgin Orbit's Chapter 11 bankruptcy auction. Rocket Lab's successful bid of approximately $16.1M includes the assumption of the lease to Virgin Orbit's 144,000+ square foot headquarters and manufacturing complex at 4022 E. Conant St. in Long Beach, California, and certain production assets, machinery, and equipment located there. The successful bid does not include the purchase of Virgin Orbit's Boeing 747 aircraft, launch vehicles or mobile launch assets for its rockets, or other Virgin Orbit facilities, inventory and assets. The purchase remains subject to finalizing the purchase agreement and approval of the United States Bankruptcy Court for the District of Delaware administering Virgin Orbit's Chapter 11 bankruptcy cases and other customary closing conditions. The combination of these assets with Rocket Lab's existing production, manufacturing, and test capabilities is expected to advance the production of Rocket Lab's larger launch vehicle, Neutron. Rocket Lab will not be integrating Virgin Orbit's launch system within its existing launch services.

18:29 EDT Ennis acquires real estate and operating assets of Stylecraft - Ennis announced its acquisition of the real estate and operating assets of Stylecraft Printing Company in Canton, Michigan. Stylecraft is a trade only printer since 1967 specializing in business forms, integrated products and commercial printing. Upon closing, Stylecraft Printing will continue its normal operations at its current locations in Canton, Michigan.

17:44 EDT Innoviva trading halted, news pending

17:37 EDT Roth CH Acquisition IV, Tigo Energy complete combination - Roth CH Acquisition IV announced the completion of its business combination with Tigo Energy, Inc. ("Tigo", or the "Company"), a leading provider of intelligent solar and energy storage solutions. The Business Combination was approved by ROCG shareholders in a special meeting held on May 18, 2023, and formally closed today. The combined company will operate under the name "Tigo Energy, Inc." and will be led by Tigo's senior management, who will continue to serve in their current roles. Commencing at the open of trading on May 24, 2023, Tigo's common stock will trade on Nasdaq under the ticker symbol "TYGO."

17:34 EDT PTC Therapeutics down 21% after announced gene therapy program discontinuation

17:26 EDT PTC Therapeutics terminates employment of CFO Emily Hill - According to a regulatory filing, on May 20, 2023, PTC Therapeutics informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer. Pursuant to Ms. Hill's employment agreement, Ms. Hill will be entitled to certain severance benefits in exchange for the execution of a general separation and release agreement as Hill's employment is being terminated without cause.

17:23 EDT Lockheed Martin awarded $194.74M Navy contract - Lockheed Martin was awarded a $194.74M firm-fixed-price and cost-plus-fixed-fee contract for MK 41 Vertical Launching System, or VLS, modules and ancillary hardware in support of fiscal 2022-2027 MK 41 VLS production requirements. This contract includes options which, if exercised, would bring the cumulative value of this contract to $642.91M. This contract combines purchases for the Navy and the governments of Canada and Australia under the Foreign Military Sales, or FMS, program. Work is expected to be completed by June 2027. If all options are exercised, work will continue through July 2030. This contract was competitively procured via the System for Award Management website, with two offers received. The Naval Sea Systems Command is the contracting activity.

17:21 EDT Delta names Michael Spanos COO - In a regulatory filing, Delta Air Lines (DAL) announced the appointment of Michael Spanos as the company's Chief Operating Officer, effective June 12, 2023. Prior to joining Delta, Spanos served as President and Chief Executive Officer of Six Flags Entertainment Corporation (SIX) from November 2019 to November 2021.

17:06 EDT VF Corp. says continued stellar performance from North Face - Says Vans was down as expected. Says very strong growth in Japan. Says says reduced inventory by $300M in Q4. Says customer service generally returned to target levels two years ahead of plan. Says aspects of the business are still underperforming. Comments taken from Q4 earnings conference call.

16:55 EDT Palo Alto Networks says deal scrutiny has increased - Says size of transactions is increasing. Sees continued path to success with large customers. Seeing limited underlying growth in hardware in the industry. Says software driving network security business. Says customers are expecting global growth to slow. Expects to drive better margins going forward. Says achieved significant acceleration in AI-based innovation in FY22, FY23 to network security stack. Says Cortex achieved $1B bookings milestone over past year. Says XSIAM on track to be fastest growing new offering. Comments taken from Q3 earnings conference call.

16:39 EDT Toll Brothers sees FY23 deliveries 8,900-9,500 - Sees FY23 average delivered price per home $975,000-$995,000. Sees FY23 tax rate 25.7%.

16:37 EDT Toll Brothers sees Q3 deliveries 2,350-2,450 - Sees Q3 average delivered price per home $1.01M-$1.03M. Sees Q3 tax rate 26%.

16:32 EDT VIA Optronics receives NYSE notice of failure to satisfy listing rule - On May 17, 2023, VIA optronics AG received an expected notice from the New York Stock Exchange stating that the company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria outlined in Section 802.01E of the NYSE Listed Company Manual due to the delay in filing the company's Annual Report on Form 20-F for the fiscal year ended December 31, 2022. The company reported in a Form 12b-25 filed with the Securities and Exchange Commission on May 2, 2023, that it was unable to file its 2022 Form 20-F within the prescribed time period without unreasonable effort or expense and needed to extend the filing deadline for its 2022 Form 20-F by the 15 calendar days allotted under Rule 12b-25. As of May 16, 2023, the company required additional time to complete year end procedures and disclosures; therefore, the company was unable to file its 2022 Form 20-F by the Extended Filing Deadline.

16:31 EDT Landstar System down 5% after cutting Q2 revenue, earnings outlook - Landstar shares are down $8.11, or 5%, to $166.95 in after-hours trading.

16:30 EDT Granite awarded $29M California DOT project - Granite was awarded an approximately $29M contract by the California Department of Transportation to widen a section of Highway 1 in Santa Cruz, California. The project is funded by the Santa Cruz County Regional Transportation Commission, with Local Measure D-Highway Corridor funds, Senate Bill 1 grants, as well as other SCCRTC discretionary funds used to complete the work necessary to ready the project for construction. The project was included in Granite's 2022 fourth-quarter CAP.

16:24 EDT Origin Bancorp exec buys $463.8K in common stock - In a regulatory filing, Origin Bancorp disclosed that its Chief Risk Officer Jim Crotwell bought 15.5K shares of common stock on May 22nd in a total transaction size of $463.8K.

16:21 EDT Henry Schein CSO Mlotek sells nearly 25,000 common shares - In a regulatory filing, Henry Schein chief strategic officer Mark Mlotek disclosed the sale of 24,747 common shares of the company on May 19 at a price of $76.68 per share.

16:19 EDT Hyzon Motors receives Second Additional Staff Determination from NASDAQ - Hyzon Motors announced that on May 17 it received a Second Additional Staff Determination from the Listing Qualifications Staff of the Nasdaq Stock Market stating that because the Company has not yet filed its Form 10-Q for the period ended March 31 the Company does not comply with Nasdaq's Listing Rules for continued listing. Hyzon has been requested by the Staff to present its views with respect to this additional deficiency to the Nasdaq Hearings Panel in writing no later than May 24. In view of the Hearings Panel's decision granting the Company's request for extension to file the Q1 Form 10-Q by June 7 the Company intends to respond to the Second Additional Staff Determination by May 24 to present the Company's views with respect to this additional deficiency.

16:18 EDT Duckhorn Portfolio names Jennifer Fall Jung CFO - The Duckhorn Portfolio (NAPA) announced Jennifer Fall Jung has been appointed Executive Vice President, Chief Financial Officer, effective June 19, 2023. Fall Jung brings more than 25 years of corporate finance and investor-focused experience to The Duckhorn Portfolio, having most recently served as Chief Financial Officer of Funko (FNKO). "I could not be more excited to welcome Jennifer to The Duckhorn Portfolio," said Alex Ryan, President, Chief Executive Officer and Chairman of the Company. "She is a deeply talented finance executive with a proven track record of devising and leading successful strategic efforts at iconic consumer products companies. Jennifer's public company and investor relations experience will be instrumental to our team as we mature as a public company and continuously strive for excellence in meeting our investors' needs and driving shareholder value. Her financial acumen, coupled with her experience in operations, and deep understanding of how to build brand equity in key markets position her to make meaningful contributions to all aspects of our business."

16:15 EDT Inovio's INO-3107 granted orphan drug designation from EC - INOVIO announced that the European Commission, or EC, has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis, or RRP. INO-3107 is an investigational DNA medicine candidate designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types that cause RRP and other HPV-related diseases.

16:11 EDT AgeX Therapeutics announces appeal of NYSE American Determination - AgeX Therapeutics announced that on May 17, 2023 it received a notice from the staff of the NYSE American indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX's non-compliance with the stockholders' equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange's Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. AgeX has the right to appeal this determination to a committee of the Board of Directors of the Exchange. AgeX intends to timely request a hearing before the Committee, and that request will stay any further action by the Exchange at least pending the issuance of a decision by the Committee on the appeal. There can be no assurance that AgeX's request for continued listing will be granted. AgeX intends to make arrangements to have its common stock quoted on an electronic interdealer quotation system if its common stock is delisted from the Exchange.

16:09 EDT Atea Pharmaceuticals confirms receipt of Concentra Biosciences proposal - Atea Pharmaceuticals confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right, or CVR, representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea's programs. Atea's board of directors and management team regularly review opportunities to generate shareholder value and are committed to acting in the best interests of all shareholders.

16:08 EDT PTC announces gene therapy program discontinuation and workforce reduction - PTC Therapeutics announced the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. PTC will continue its development and global commercialization of Upstaza, the first-ever approved gene therapy directly administered to the brain. As a result of the prioritization, estimated reductions of approximately fifteen percent in residual 2023 operating expenses, or OPEX, are expected. Additional 2023 OPEX guidance will be provided as part of Q2 earnings. The decision to deprioritize early-stage gene therapy programs reflects the company's desire to focus resources on areas of the pipeline likely to deliver significant return on investment and transformative therapies for patients with high unmet medical need. The discontinuation of the gene therapy programs will also result in a reduction in workforce which will be conducted in accordance with appropriate labor regulations. In addition, PTC Therapeutics also announced that PTC's CFO Emily Hill has been relieved of her responsibilities and will be leaving the organization.

16:03 EDT Intuit sees average revenue per return up 12% - The company states: "Third quarter Consumer Group revenue growth reflects Intuit's expectations for the full fiscal year, including: A decline in total IRS returns of 2%, and a decline in DIY category share of nearly three quarters of a point. The company believes this was driven by taxpayers who filed in order to receive pandemic-era stimulus and tax credits during the past several years but did not file taxes this season. For the same reasons as above, TurboTax share of total IRS returns to decline approximately 80 basis points, total TurboTax units to decline 5%, and TurboTax Online paying units to decline 1%. Average revenue per return to increase approximately 12%, as the company expects TurboTax Live revenue to grow approximately 19% and TurboTax Live customers to grow approximately 13%."

15:48 EDT McEwen Mining says Sprott no longer a lender after senior secured debt repayment - McEwen Mining reported that it has repaid $25M of its senior secured debt payable to Sprott Resource Lending and Sprott is no longer a lender. "Prior to the repayment, the company had $50M in senior secured debt and a $15M unsecured promissory note, for a total debt of $65M. Concurrent with the repayment to Sprott, the senior secured debt was amended and restated in the amount of $40M bearing monthly interest at 9.75% per annum, and the promissory note was extinguished. The company's sole lender is now an entity owned by our Chairman and Chief Owner Rob McEwen. As a result of the debt reduction, McEwen Mining's annual borrowing costs will decrease by approximately $2.2M, or 36%," the company stated.

15:06 EDT Ocean Biomedical spikes over 50% after patent award in cancer immunotherapy - Shares of biopharma company, Ocean Biomedical, are up 56% or approximately $3 per share in late day trading on Tuesday, after announcing that its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing immune system suppression by binding chitinase 3-like-1, CHi3L1, polypeptides with Ocean Biomedical's proprietary immunoglobulin antibody. This process has been shown to suppress primary and metastatic tumor growth in multiple animal models and has potential use in multiple forms of visceral cancers..."These discoveries have the potential to save thousands of lives of people affected not just by lung metastasis, and melanoma, but also glioblastoma and other forms of cancer," commented Dr. Chirinjeev Kathuria, Ocean Biomedical's co-founder and Executive Chairman.

15:02 EDT Nvidia integrating AI Enterprise software into Microsoft Azure Machine Learning - Nvidia (NVDA) announced at Microsoft Build that it is integrating its Nvidia AI Enterprise software into Microsoft's (MSFT) Azure Machine Learning to help enterprises accelerate their AI initiatives. "The integration will create a secure, enterprise-ready platform that enables Azure customers worldwide to quickly build, deploy and manage customized applications using the more than 100 Nvidia AI frameworks and tools that come fully supported in Nvidia AI Enterprise, the software layer of Nvidia's AI platform," the company stated. The Nvidia AI Enterprise integration with Azure Machine Learning is available in a limited technical preview in the Nvidia community registry, the company noted. "With the coming wave of generative AI applications, enterprises are seeking secure accelerated tools and services that drive innovation. The combination of Nvidia AI Enterprise software and Azure Machine Learning will help enterprises speed up their AI initiatives with a straight, efficient path from development to production," added Manuvir Das, vice president of enterprise computing at Nvidia.

14:53 EDT Norfolk Southern and twelve labor unions commit to team on rail safety - Norfolk Southern Corporation President and CEO Alan H. Shaw and leaders of 12 Norfolk Southern labor unions sent a joint letter Tuesday underscoring their shared goal of partnering together to drive continuous improvement in rail safety at the company. The letter was sent to all Norfolk Southern craft and management employees. The signatories wrote in the letter:".., national labor leaders and Norfolk Southern management are committing to work together to enhance rail safety for our people and the communities we serve. We won't agree on everything. That's okay. Our belief in the importance of safety unites us. We want our people to show up to work every day knowing their employer and their union are working diligently to help them do their jobs safely. We will collaborate, consult experts, review best practices, and listen to the people closest to the work. Working together - and broadening the conversation to ensure everyone plays a part - is the best way to achieve meaningful improvement. We will remain open-minded, nimble, and fact-based, making changes as we learn. Along the way we will continue to look for other ways to collaborate to improve the quality of life for our colleagues. Union representatives signing the letter include the national presidents of the American Train Dispatchers Association; Brotherhood of Locomotive Engineers and Trainmen; Brotherhood of Maintenance of Way Employes; Brotherhood of Railroad Signalmen; International Association of Sheet Metal, Air, Rail and Transportation Workers - Transportation Division; and Transportation Communications Union.

14:25 EDT Evoqua Water says received all regulatory approvals needed for Xylem merger - In a regulatory filing, Evoqua Water (AQUA) noted that, as previously announced on January 22, Evoqua Water entered into an agreement and plan of merger with Xylem (XYL). On May 23, the company announced that the company and Xylem have received all regulatory approvals required to consummate the merger. The company and Xylem currently anticipate that the closing of the merger will occur on or about May 24, subject to the satisfaction, or, to the extent permitted by applicable law, waiver, of the conditions set forth in the merger agreement that by their nature are to be satisfied at the closing of the merger, the filing said.

14:05 EDT Wyndham Hotels up 11% tp $73.17 after WSJ report of Choice interest

14:01 EDT Choice Hotels falls 4% following WSJ report of Wyndham interest

13:54 EDT Mereo BioPharma presents data from Phase 2 ASTRAEUS trial at ATS2023 - Mereo BioPharma announced that data from the Phase 2 "ASTRAEUS" trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, or AATD-LD, as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ, a key Patient-Reported Outcome measure, were presented for the first time to the scientific community at the 2023 American Thoracic Society International Conference. The ASTRAEUS data were presented during an oral abstract session on novel treatments and targets by Prof. Robert Stockley, Lung Investigation Unit, University of Birmingham and Chief Investigator of the ASTRAEUS trial, while the post-hoc analyses were presented in a poster session by Dr. Jackie Parkin, Senior Vice President and Therapeutic Head at Mereo. "We are very pleased to have these data presented to the scientific community for the first time at ATS2023. These findings have informed our recent and ongoing discussions with both the FDA and EMA, and validate the proposed design for our planned Phase 3 trial, which we believe will be the first registrational study in AATD-LD to use both a PRO approach and an objective clinical outcome measure as independent primary endpoints. We are excited by the potential of alvelestat to become the first-in-class oral neutrophil elastase inhibitor for the treatment of AATD-LD and look forward to continued collaboration with the regulatory authorities, scientific and patient communities as we further refine our development plans ahead of the pivotal study. We look forward to sharing further updates on the progress of the alvelestat program, including the results of the investigator-led Phase 2 ATALANTA study evaluating alvelestat in combination with augmentation therapy, which is expected to read out in Q3 2023," said Dr. Denise Scots-Knight, CEO of Mereo BioPharma.

13:10 EDT Stephen Marcus to step down as chairman of Marcus board, to be chairman emeritus - The board of directors of The Marcus Corporation have appointed Stephen Marcus as non-director chairman emeritus and special advisor to the company. Steve Marcus notified the board of directors that he is stepping down as chairman of the board effective today, the date of the 2023 annual meeting of shareholders, the company announced. The board of directors also unanimously appointed Gregory Marcus as chairman of the board. In addition to his role as chairman, Greg Marcus will continue to serve as CEO and president of The Marcus Corporation, the company stated.

13:02 EDT Dell Technologies, Nvidia to partner around on-premises generative AI - Dell Technologies (DELL) and Nvidia (NVDA) announce a joint initiative to "make it easier for businesses to build and use generative AI models on-premises to quickly and securely deliver better customer service, market intelligence, enterprise search and a range of other capabilities," called Project Helix. "Project Helix will deliver a series of full-stack solutions with technical expertise and pre-built tools based on Dell and NVIDIA infrastructure and software. It includes a complete blueprint to help enterprises use their proprietary data and more easily deploy generative AI responsibly and accurately," the companies stated. "Project Helix gives enterprises purpose-built AI models to more quickly and securely gain value from the immense amounts of data underused today. With highly scalable and efficient infrastructure, enterprises can create a new wave of generative AI solutions that can reinvent their industries," added Jeff Clarke, vice chairman and co-chief operating officer, Dell Technologies.

12:32 EDT CVR Energy falls amid fire at refinery in Oklahoma - CVR Energy fire crews are fighting a blaze that broke out Tuesday at its Wynnewood refinery in Oklahoma, people familiar with operations told Bloomberg. The fire occurred at a unit that makes renewable-diesel product and two workers suffered burns, Bloomberg reports. CVR said the source of the fire has been isolated. Shares of CVR Energy are down 2% to $24.85 in midday trading.

12:14 EDT Doma Holdings trading resumes

12:00 EDT Daily S&P Biotech Bear 3x Shares falls -6.8% - Daily S&P Biotech Bear 3x Shares is down -6.8%, or -86c to $11.74.

12:00 EDT Navigator Holdings rises 11.6% - Navigator Holdings is up 11.6%, or $1.53 to $14.67.

12:00 EDT Natuzzi rises 13.6% - Natuzzi is up 13.6%, or 69c to $5.80.

11:49 EDT Match Group CFO says Tinder acceleration seen in April continued into May - Asked during JPMorgan's Technology, Media and Communications conference about the company's recent shareholder letter chart that showed Tinder subscription revenue in the U.S. accelerating through April and whether this trend continued through May, Match Group CFO Gary Swidler replied, according to a transcript of the event: "There's more work to do, and I don't want to minimize everything we need to do as the year progresses. There's a lot of initiatives underway at Tinder as BK started to go through. But the benefits of having rolled out the pricing changes in the U.S. and then having rolled them out in the international markets, does help give us confidence that by the time we get to Q4, we have a sense that we can do 10-plus percent year-over-year revenue growth. And yes, to answer your other part of your question, the April trends have continued into May. So that's increasing our confidence. Now instead of 4 weeks, we've had 7 weeks of similar trends. So that's obviously very encouraging and meaningful extra data points for us and increased confidence that what we said about the back half of the year is coming to fruition. And so we're feeling good about that... Subscription revenue continues to be up nicely year-over-year. And as I mentioned, we're seeing some increases in a la carte as well because of weekly subscriptions and some changes we've made on the Boost a la carte feature as well. So things are starting to flow there as well, which, again, gives us more confidence that we can achieve our financial objectives."

11:34 EDT Sigilon Therapeutics trading halted, volatility trading pause

11:11 EDT Comcast announces NOW TV streaming offering - Comcast unveiled NOW TV, a streaming offering that "includes 40+ live channels from A&E, AMC, Hallmark and Warner Bros. Discovery, plus 20+ integrated FAST channels from NBC, Sky and Xumo Play, and a subscription to Peacock Premium at no additional cost." Comcast said: "NOW TV was built to meet the needs of the value-conscious consumer who wants an entertainment product that is simple and convenient with quality programming movies, top shows, live sports, and news. Launching in the coming weeks, NOW TV will be available to Xfinity Internet customers for an everyday monthly price of $20, no equipment required, and the ability to sign up and cancel anytime." At launch, NOW TV Live and Xfinity Stream's FAST channels will be accessible through the Xfinity Stream app on supported devices, including Xfinity Flex, Fire TV, iOS and Android-powered devices, and via casting through Apple AirPlay and Google Chromecast, the company noted.

10:50 EDT Verde Clean Fuels Inc trading halted, volatility trading pause

10:23 EDT Peloton to offer five distinct Membership tiers - Peloton will now offer five distinct Membership tiers, inclusive of three newly launched App Membership Tiers, as well as the existing All Access Membership and Guide Membership. The company said, "The new App tiers allow beginners and enthusiasts alike to work out with or without equipment - at home, outdoors or at their gym - independently or with instruction. In addition, for the first time, Peloton Row content will be available on the App. Across all App tiers, Peloton Members will have access to expert instruction; the ability to track workouts with the Just Work Out feature; and the fitness industry's leading music library. The new App tiers allow users to personalize their Peloton experience to suit their daily fitness needs - which, for many, vary on a daily basis: Peloton App Free - Designed to supplement a user's current workout routine or as a taste-test of all Peloton has to offer for a newbie. This tier currently provides more than 50 classes curated across 12 of Peloton's modalities to enable the user to pair workouts to meet their individual interests, even as those goals change over time. It will also include a rotating set of featured classes that will be refreshed on an ongoing basis. Peloton App One - Designed for the Member who wants unlimited access to thousands of classes across 9 of Peloton's 16 modalities, including Strength, Meditation, Outdoor Walking, Yoga, and more as well as all the classes included in the free tier. App One Members can also take up to three equipment-based cardio classes per month. New on-demand and live classes will be offered almost daily as well as access to Peloton's Challenges, Programs, and Collections. $12.99 per month, $129 per year. Peloton App+ - Designed for the user who wants frictionless, unlimited access to Peloton's vast library. This tier includes all of App One's offerings and unlocks access to thousands of equipment-based cardio classes to take on any indoor bike, treadmill, or rower. This tier also offers exclusive access to classes, featuring the latest specialty content. $24 per month, $240 per year."

10:20 EDT Peloton launches new brand identity, creative campaign - Peloton announced the start of the company's next chapter as it repositions from the perception of an in-home bike company to reflect everything Peloton has to offer. The company said, "With Peloton's amazing content on its award-winning hardware and App, today's relaunch ignites a vibrant new brand identity and campaign; introduces new Membership tiers; and releases a new content feature, Peloton Gym. With today's relaunch, Peloton is declaring itself open and available for everyone to experience its expert Instructors and world-class content, even for free. Dynamic. Vibrant. Boundless. Authentic. Peloton's new campaign brings forward the company's fitness offerings for all ages, levels, and walks of life. The new brand identity features a bold color palette that evokes the energy of a great workout and the afterglow that follows. It includes powerful still imagery of actual Members showcasing that before-and-after emotion. Peloton drove the brand strategy, partnering with both Mother Design and Uncommon Creative Studio on the new brand expression. Stink Studios was appointed for global creative, collaborating with Peloton's own internal creative studio, and Stink Films director Jones. The new brand identity launches globally along with a new creative campaign in the US and Canada. Local market creative campaigns will roll out later this year."

10:08 EDT Greencity Acquisition receives notice of non-compliance from Nasdaq - Greencity Acquisition announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market on May 22, 2023. The Notice advised the Company that based on Staff's review and the materials submitted by the Company on April 18 and May 12, 2023, the Staff has determined to deny the Company's request for continued listing on The Nasdaq Capital Market. Accordingly, the Company's securities will be delisted from The Nasdaq Stock Market. In that regard, unless the Company requests an appeal of this determination, trading of the Company's securities will be suspended at the opening of business on June 1, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company may appeal Staff's determination to a Hearings Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Requests for a hearing and for an extended stay should be submitted electronically through the Nasdaq Listing Center, and must be received no later than 4:00 Eastern Time on May 30, 2023.

10:02 EDT CoreSite expands data center footprint in Silicon Valley, Denver campuses - CoreSite announced the continued expansion of its Silicon Valley and Denver data center campuses to meet the dynamic digital infrastructure requirements of public and private cloud providers, enterprises, network and service providers. As a leading interconnection provider, CoreSite is adding its ninth data center in Santa Clara, California. With the addition of the new 240,000-square-foot, purpose-built data center - known as SV9 - the company's newest Silicon Valley data center campus will have 1.179 million total square feet of data center space. Located at 2915 Stender Way, SV9 will offer 34 megawatts of IT load with a new utility substation onsite. CoreSite has also completed the design and permitting process to add 3,420 square feet and 500 kilowatts of IT load to its downtown Denver data center at 910 15th Street, one of the most interconnected data centers in the Denver metro region.

10:00 EDT Eve Holding falls -5.8% - Eve Holding is down -5.8%, or -52c to $8.38.

10:00 EDT Palantir rises 7.3% - Palantir is up 7.3%, or 86c to $12.70.

10:00 EDT Yelp rises 10.5% - Yelp is up 10.5%, or $3.42 to $35.94.

09:56 EDT Citizens Bank to pay $9M penalty to CFPB for unlawful credit card servicing - The Consumer Financial Protection Bureau said it has reached a settlement to resolve allegations that Citizens Bank violated consumer financial protection laws and rules that protect individuals when they dispute credit card transactions. The CFPB alleges that Citizens Bank failed to properly manage and respond to customers' credit card disputes and fraud claims. If entered by the court, the order, among other things, would require Citizens Bank to pay a $9M civil money penalty. "Federal law provides important rights to credit cardholders when disputing transactions and resolving billing errors," said CFPB Director Rohit Chopra. "As outstanding credit card debt approaches $1T, the CFPB will be closely watching the conduct of the credit card industry."

09:49 EDT Roth CH Acquisition IV Co trading resumes

09:47 EDT X Financial falls -5.5% - X Financial is down -5.5%, or -18c to $3.08.

09:47 EDT Endava falls -11.4% - Endava is down -11.4%, or -$6.39 to $49.74.

09:47 EDT Navigator Holdings rises 8.7% - Navigator Holdings is up 8.7%, or $1.15 to $14.29.

09:46 EDT Theralink to be acquired by IMAC Holdings in stock-for-stock reverse merger - Theralink Technologies (THER) and IMAC Holdings (IMAC) announced that they have entered into a definitive Agreement and Plan of Merger under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine. The Theralink Test for Advanced Breast Cancer measures the abundance and activation of 32 clinically actionable biomarkers. The test reports which of the 32 biomarkers are highly expressed or activated and the FDA-approved therapeutics that target them. This test is a novel tool that broadens actionability and supports oncologists in selecting the most effective treatment plan for their cancer patients. Recently, Theralink received a Medicare reimbursement rate determination as well as added to its evidence based clinical utility data via an observational registry study that demonstrated greater than 90% actionability and greater than 70% clinical utility for the test. The Theralink test may be deemed necessary to achieve a personalized and targeted approach to breast cancer treatment The Merger is structured as a stock for stock reverse merger whereby all of Theralink's outstanding equity interests are to be exchanged for shares of IMAC common stock. Theralink stakeholders are expected to own approximately 85% of the combined company, and pre-merger IMAC equity holders are expected to own approximately 15% of the combined company, on a fully diluted basis calculated using the treasury stock method, subject to certain adjustments provided for in the Merger Agreement. The boards of directors of both companies have unanimously approved the Merger Agreement. The merger is expected to close late in the third quarter or early in the fourth quarter of 2023, subject to satisfying certain closing conditions, including the completion of satisfactory due diligence by both parties and the receipt of shareholder approval by both companies. All current IMAC directors but one will resign effective upon the closing of the Merger, and the existing directors of Theralink shall be appointed to the board of IMAC, with Jeffrey Busch to serve as Chairman.

09:42 EDT Knightscope signs contract with University of Nevada, Reno - Knightscope announced a new contract with the University of Nevada, Reno. The University is subscribing to Knightscope's K5 Autonomous Security Robot service that uses robotics and artificial intelligence to provide 24/7/365 patrols in support of the University Police Department - Northern Command. The K5 ASR will patrol the parking garage located near the Student Center, helping students stay safe during class time, around games and other events, and throughout each night.

09:39 EDT Transcode Therapeutics Inc trading halted, volatility trading pause

09:29 EDT Broadcom up 2% after Apple announces 'multibillion-dollar' supply deal - Broadcom (AVGO) shares are up $12.64, or 2%, to $691.01 in pre-market trading ahead of the opening bell following Apple's (AAPL) announcement of the supply agreement.

09:25 EDT Lowe's seeing increased demand in paint, especially from Pro's - Says Pro's reported shift to smaller project sizes. Says scaling rural framework. Says getting more strategic in inventory planning. Seeing best staffing levels, retention, in three years.

09:24 EDT Lexaria Bioscience announces additional results from HYPER-H21-4 study - Lexaria Bioscience announced additional findings from last year's human clinical study HYPER-H21-4 demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease and a host of other conditions. After five weeks of treatment with the patented DehydraTECH-processed cannabidiol capsule formulation, blood-plasma levels of interleukin ("IL") 8, 10, and 18 were reduced by ~19%, ~27%, and ~43%, respectively. Those persons receiving five weeks of placebo experienced no significant changes in their IL levels as shown with the black bars in the graph below. The differences evidenced relative to baseline and/or placebo with pro-inflammatory biomarkers IL 8, 10 and 18 were statistically significant. There is clear scientific evidence for the involvement of IL-8 in the establishment and preservation of the inflammatory microenvironment of the vascular wall in instances of CVD. In cardiovascular risk estimation, several reports have indicated that increased serum levels of IL-8 are correlated with an increased risk of CVD or acute cardiovascular events. IL-10 and IL-18 are also considered anti-atherosclerotic cytokines with evidence for IL-8 and IL-18 perhaps being even stronger in CVD. In addition, IL-10 levels are known to increase along with the reduction of kidney function; and higher serum IL-10 levels have been associated with the risk of cardiovascular events during follow-up. Similarly, IL-18 is an independent predictor of cardiovascular events in patients with metabolic syndrome. In large population-based studies, circulating IL-18 is prospectively and independently associated with CVD risk. Lexaria previously announced that the primary efficacy and safety objectives of the Study were successfully achieved, with resting blood pressure significantly reduced in hypertensive patients, and sustained over the full 5-weeks of dosing with zero serious adverse events being reported throughout the Study. Lexaria is aware of only a handful of other published research studies, mostly in young, healthy and normotensive volunteers, that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing; none of which have been successful in achieving this. In addition, Lexaria also previously announced data from the Study revealing potentially a unique mechanistic benefit upon cardiovascular regulation via catestatin modulation with DehydraTECH-CBD treatment that has not previously been demonstrated with testing of CBD for blood pressure reduction to its knowledge. This finding together with today's announcement of improvements in pro-inflammatory biomarker levels related to cardiovascular and related disease states further strengthens the case for DehydraTECH-CBD offering distinctive mechanistic benefits related to its growing therapeutic utility. These reductions in inflammation also provide an mechanistic additional pathway by which DehydraTECH-CBD may act to lower blood pressure.

09:18 EDT Monogram Orthopaedics engages MZ Group for investor relations - Monogram Orthopaedics engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Monogram management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Monogram's work to develop a product solution architecture with the long-term goal to enable patient-optimized orthopedic implants economically at scale by linking 3D printing and robotics with advanced pre-operative imaging. Monogram has a robot prototype that can autonomously execute optimized paths for high precision insertion of implants in synthetic bone specimens.

09:16 EDT Broadcom reports two separate multi-year statements of work with Apple - In a regulatory filing, Broadcom (AVGO) disclosed: "Certain subsidiaries of Broadcom Inc. have entered into two separate multi-year statements of work with Apple Inc. (AAPL). The 2023 SOWs are for the supply of a range of specified high-performance RF and wireless components and modules for use in Apple products. Pursuant to the 2023 SOWs, Broadcom has agreed to supply Apple with specified components and modules for Apple products and to maintain and allocate to them sufficient manufacturing capacity and other resources to make these products."

09:12 EDT Vicor announces Doosan Mobility appeared on its podcast - Doosan Mobility Innovation appeared on the Vicor Powering Innovation podcast to discuss the life-saving applications they support with their hydrogen fuel-cell power pack, which enables drones to fly 5x longer than those utilizing lithium-ion batteries. In the latest episode, Doosan, a Korea-based company, shares a variety of life-saving applications where drones are the hero, serving as first-responders in a number of long-distance rescue missions. "Our Vicor Powering Innovation podcast continues to spotlight captivating technological advancements that are changing our world," said Robert Gendron, Corporate Vice President of Product Development for Vicor. "In my conversation with Doosan, we explore their use of hydrogen fuel-cell power packs to power their drones. Soonsuk and his team are focused on leveraging hydrogen fuel cells to enable longer flight times for the drones, which opens up the possibility of supporting a wider variety of applications. They are doing remarkable things today to save lives and help people."

09:11 EDT Environmental Solutions enters joint development agreement with Nanomatics - Environmental Solutions Group Holdings announced that it has entered into a joint development agreement, JDA, with Nanomatics to develop and advance jointly proprietary technologies to convert plastic waste to pyrolysis oil, carbon nanotubes and hydrogen. ESGL, through its operating entity in Singapore, Environmental Solutions Pte. Ltd., is a sustainable waste solutions provider whose mission is to recycle industrial waste into circular products using innovative technologies and renewable energy. The two companies have evaluated the economic feasibility of a partnership for the joint development of a process combining their respective strengths to manufacture pyrolysis oil, carbon nanotubes and hydrogen from plastic waste. The main objective of this JDA is to further develop and apply at scale NMT's THERMO-CVD Process Technology at ESA's pilot plant facility to primarily produce carbon nanotubesi and hydrogen from plastic waste and synthetic gas generated using ESA's FR-3 Pyrolysis Technology. On November 30, 2022, Genesis Unicorn Capital, a special purpose acquisition company, announced that it had signed a definitive merger agreement with ESGL.

09:09 EDT Asana Partners selects DealCloud for deal, relationship management - Intapp announced that Asana Partners has selected DealCloud to centralize and unify firm data. Using DealCloud as its centralized technology platform, Asana Partners will enable firmwide knowledge capture and increase operational efficiencies. DealCloud will be used by the firm's capital markets team to track investor relationships and fundraises, by its acquisition team to track pipeline and associated relationships, and by its leasing team to track interactions with brokers and tenants.

09:08 EDT AMD announces new lineup of AMD Ryzen, Athlon 7020 C-Series processors - AMD announced the new lineup of AMD Ryzen and Athlon 7020 C-Series processors, bringing modern performance and technologies to everyday Chromebooks. With speeds of up to 4.3 GHz, up to four cores and eight threads built on proven "Zen 2" architecture, and powerful AMD RDNA 2 integrated graphics, these processors are engineered to deliver fast and responsive performance for modern productivity, video conferencing, learning apps, and streaming applications

09:06 EDT Tenable Holdings, Splunk launch strategic partnership - Tenable announced a strategic partnership with Splunk to enable security teams to better correlate events, take action on flaws and meet compliance standards. The combined power of Tenable's vulnerability management insights with Splunk's log and flow consolidation capabilities simplifies risk prioritization and accelerates threat response, ultimately reducing overall business risk. Tenable provides Splunk customers with full visibility into all assets, and continually assesses those assets for exposures and vulnerabilities, assigning each weakness a Vulnerability Prioritization Rating.

09:06 EDT Perion Network falls 5% in pre-market trading following Spruce Point short call

09:05 EDT Spruce Point issues short report on Perion Network, sees up to 40% downside risk - Spruce Point Capital Management "issued a detailed report entitled "Searching For Answers" that outlines why we believe shares of Perion Network Ltd. face up to 25% to 40% long-term downside risk, or $19.10 - $23.85 per share." Spruce Point outlines its concerns with the stock, stating: "Search business appears to be under pressure and over-reliant on a Microsoft (MSFT) partnership where revenues appear to be falling below plan while reporting anomalies emerge", also noting "multiple concerns with Perion's revenue reporting and sustainability of recent financial performance." The short seller further writes that "Perion's capital raising practices are troubling, and Spruce Point believes that Perion's financing activities are a major red flag." Reference Link

09:05 EDT Y-mAbs Therapeutics announces approval of DANYELZA in Brazil - Y-mAbs Therapeutics announced that the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria has granted marketing authorization for DANYELZA 40mg/10mL injection. DANYELZA will be marketed in Brazil by Y-mAbs' partner Adium Pharma. DANYELZA is a recombinant humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered to patients three times in a week and the treatment is repeated every four weeks.

09:03 EDT Riot Platforms to constitute advisory board - Riot Platforms is constituting an Advisory Board, which will reflect Riot's commitment to having world-class talent provide advisory services to its executive leadership team and Board of Directors. Riot's first Advisory Board member will be Brad Jones, the former Interim President and CEO of the Energy Reliability Council of Texas, which manages ninety percent of the state's power supply, monitoring over 50,000 miles of transmission lines and over 1,100 power generation units. Riot continues to conduct a thorough review process to engage additional Advisory Board members with expertise in the fields of electrical grid and power management, power generation development, legislative and regulatory processes, financial services, and capital markets.

09:02 EDT Telus to invest $19B in Alberta through 2027 - TELUS announced an investment of $19 billion to build and develop network infrastructure, operations, and spectrum across Alberta over the next five years as part of its commitment to invest $81 billion across Canada by 2027.These investments are critical to providing Canadians with access to superior technology, connecting customers to the people, resources and information that make their lives better. Since 2000, TELUS has invested more than $57 billion in Alberta alone, building global leading industry networks and has been recognized as Alberta's top broadband network by Opensignal.

09:02 EDT Telus to invest $18.5B in British Columbia through 2027 - TELUS announced an investment of $18.5 billion to build and develop network infrastructure, operations, and spectrum across British Columbia over the next five years as part of its commitment to invest $81 billion across Canada by 2027. These investments are critical to providing Canadians with access to superior technology, connecting customers to the people, resources and information that make their lives better. Since 2000, TELUS has invested more than $59 billion in British Columbia alone, building global leading industry networks and has been recognized as B.C's top broadband network by Opensignal.

09:01 EDT Spruce Point issues short report on Perion Network

08:52 EDT Brera Holdings expands acquisition strategy to include other sports - Brera Holdings plans to expand its acquisition strategy to include other team and individual sports, in addition to football, which will remain its core business. This strategy may include the outright acquisition of men's or women's clubs or teams or simply the management or sponsorship of such clubs or teams in order to accelerate the development of their sports activity. The Company expects this will mainly be accomplished through Brera rebranding, but the Company also intends to set up a division that will work on the re-empowerment of established clubs while maintaining their original brand.

08:49 EDT Gladstone Investment announces notes offering - Gladstone Investment Corporation announced that it plans to make a public offering of Notes due 2028. The Company expects to list the Notes on the Nasdaq Global Select Market under the trading symbol "GAINL" within 30 days of issuance. Oppenheimer & Co. Inc., B. Riley Securities, Inc., Janney Montgomery Scott LLC and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers for this offering. Gladstone Securities, LLC, Piper Sandler & Co. and Wedbush Securities Inc. are acting as co-managers for this offering. The Company intends to repay a portion of the amount outstanding under its revolving credit facility, to fund new investment opportunities, and for other general corporate purposes.

08:47 EDT Yoshiharu introduces cold ramen as seasonal menu item - Yoshiharu Global has introduced a limited time cold ramen dish to be offered during the spring and summer months. The new seasonal dish is already available across all nine Yoshiharu locations for customers to enjoy.

08:46 EDT Loop Media set to join Russell 3000, 2000 and Microcap indexes June 26 - Loop Media is set to join the broad-market Russell 3000 Index, as well as Russell 2000 and Russell Microcap Indexes, at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

08:44 EDT BK Technologies receives purchase order for 2,700 BKR5000 radios - BK Technologies announced that it has received a purchase order from the United States Department of Agriculture Forest Service for its BKR 5000 portable communications technology. The purchase order is part of the Company's 5-year Blanket Purchase Agreement with the U.S. Department of Agriculture, announced in May 2021.

08:43 EDT Ameriserve Financial: U.S. court denies 'Driver' request for injunctive relief - AmeriServ Financial announced that the United States District Court for the Western District of Pennsylvania has denied Driver Opportunity Partners motion for a preliminary injunction to delay the Company's 2023 Annual Meeting of Shareholders. The Annual Meeting will take place as scheduled on May 26 .In March 2023, AmeriServ announced that its Board of Directors had determined that Driver's purported nomination notice was invalid due to material defects and failure to comply with the Company's bylaws. Driver subsequently filed a legal action with the Court. In its opinion issued this week, the Court stated that "Driver has failed to meet its burden to demonstrate it is likely to prevail on the merits of its claims [...]" The Court also declared that "Driver's inability to have its director nominees considered for election at the 2023 Annual Meeting is entirely a result of its own failures, not as a result of AmeriServ's conduct." AmeriServ is represented in legal proceedings by Stevens & Lee, P.C. and Vinson & Elkins.

08:42 EDT NetSol Technologies appoints Darryll Lewis as MD, Netsol Technologies Europe - NETSOL Technologies announced the appointment of Darryll Lewis as its new Managing Director of NETSOL Technologies Europe. He last served as Global Sales Director for Lendscape, the world's leading technology provider for all forms of secured finance and secured lending software solutions.

08:41 EDT Predictive Oncology announces upcoming presentation at 2023 BIO convention - Predictive Oncology announced that the company's Chief Business Officer, Pamela Bush, Ph.D., MBA, will present at the upcoming 2023 BIO International Convention, in Boston, Massachusetts, on June 5, 2023, at 2:45 p.m. ET, Presentation Room 103. Dr. Bush will discuss the importance of addressing patient heterogeneity in drug discovery and the advantage of leveraging active machine learning in the process. "Through our PEDAL platform, we can efficiently challenge a compound to demonstrate drug response within a set of heterogeneous tumor samples representing what the compound would encounter in a clinical trial. Thus, providing a leading indicator of clinical performance. The benefit to biopharma is that the outcome of a PEDAL campaign increases the probability of clinical success, mitigates risk and strengthens the pipeline," said Dr. Bush.

08:40 EDT Triumph Financial announces Worldwide Express joined its payments network - TriumphPay announced the addition of the Worldwide Express family of brands, which includes Worldwide Express, GlobalTranz and Unishippers, to its open payments network as a full audit and payments network participant. The TriumphPay open payments network has rapidly expanded since its launch in January 2022, creating a more secure hub for the presentment, audit, and payment of invoices in the transportation industry. "We're incredibly excited to announce the partnership between TriumphPay and Worldwide Express," said Aaron Graft, vice chairman and chief executive officer of Triumph Financial. "Worldwide Express is an innovative, technology-enabled logistics solutions provider with a track record for providing some of the best service and broadest modal offerings in the industry. Joining the TriumphPay open payments network reflects their commitment to being an unmatched leader in providing carrier services."

08:37 EDT Trust Stamp announces notice of allowance for new U.S. patent related to AI - Trust Stamp announced that it has received a Notice of Allowance for an additional patent by the United States Patent and Trademark Office related to its AI-powered, tokenized-identity products. This Notice of Allowance follows three additional patent applications announced in April, 2023. The patent, titled: "Systems and processes for lossy biometric representation," expands the IP protection around the Company's innovative biometric hashing technology used for subject identity verification. Through neural network processing and pseudorandom matrix multiplication, the technology in the patent generates anonymized vector representations of biometrics that can be compared to one another for verifying a subject's identity. These anonymized vector representations are "lossy," meaning not all information from the original biometric is included in the anonymized vector representation. Generating "lossy" representations allows for enhanced security when dealing with a subject's sensitive biometric data, while still allowing for the anonymized vector representations to be compared to one another with a degree of certainty high enough for identity verification.

08:35 EDT Cineverse announces new leadership structure and promotions - Cineverse announced the promotions of several members of its leadership team, effective immediately. Erick Opeka will continue in his role as Chief Strategy Officer for Cineverse and has been promoted to President of Cineverse. Tony Huidor has been promoted to COO & CTO. Mark Torres, HR professional with experience with media and technology companies such as Sony Pictures, Ticketmaster and Variety, has been appointed Chief People Officer. Yolanda Macias will continue her role as the Chief Content Officer. John Canning will remain as CFO. Prior to Cineverse, Canning was CFO of Firefly Systems and held previous positions at Tapjoy, Discovery Channel and The Walt Disney Company. Gary Loffredo will continue in his role as Chief Legal Officer, Secretary and Senior Advisor.

08:34 EDT Galecto completes dosing in 52-week Phase 2b GALACTIC-1 trial of GB0139 - Galecto announced the last dosing of the last patient in the GALACTIC-1 Phase 2b trial of its most advanced product candidate, GB0139, for the treatment of idiopathic pulmonary fibrosis. "We are pleased to have completed dosing in the GALACTIC-1 trial, which is a component in Galecto's quest to develop anti-fibrotic drugs," said Dr. Hans Schambye, President and Chief Executive Officer of Galecto. "GB0139 has been shown to specifically target galectin-3, one of the key regulators in IPF. Patients with IPF need new and more tolerable treatment options and we believe GB0139 has the potential to address this significant unmet medical need, while being easy to administer as a once-daily inhaled treatment. We've had significant interest in the outcome of the GALACTIC-1 trial and we plan to report topline data from this study in August 2023."

08:33 EDT LM Funding says 'stalking horse' bid to purchase Symbiont.io assets unopposed - LM Funding America announced that its $2.6M "stalking horse" bid to purchase the assets of Symbiont.io, which is currently in Chapter 11 bankruptcy proceedings, is unopposed and expected to be approved by the bankruptcy court, and an auction that could include other bids is anticipated to take place on May 26. LM Funding is currently the sole secured creditor for Symbiont as a result of a $2M secured loan it made to Symbiont in December 2021. Bruce Rodgers, Chairman, and CEO of LM Funding commented, "We are making a stalking horse bid to purchase the assets of Symbiont, including those related to its Assembly financial services blockchain enterprise platform. If we successfully acquire the assets, we intend to pursue joint ventures and/or other strategic relationships to offer Assembly to institutions to issue, track and manage financial instruments, such as data, loans, and securities. We also plan to investigate and consider other use cases for the Symbiont assets and Assembly platform."

08:33 EDT Diversified Healthcare Trust investor Flat Footed opposes Office Properties deal - Flat Footed owns approximately 7.4% of the outstanding common shares of Diversified Healthcare Trust (DHC) "making it one of the Company's largest shareholders. Today, FFL issued the below letter sent to the Company's Board of Trustees regarding DHC's recently announced definitive merger agreement with Office Properties Income Trust (OPI). In the letter, FFL outlines why it opposes and intends to vote its DHC shares AGAINST the proposed merger with OPI to protect the long-term value and interests of all Company stakeholders," said Flat Footed, in a statement. "Given our sizable investment in DHC, we believe our views merit substantial weight. It appears the Board has failed shareholders by prioritizing the external manager's interests above all else. There are many superior alternatives available to address DHC's upcoming debt maturities, such as curtailing RMR's fee-driven spending to preserve cash or a targeted sale of a small percentage of its assets, that we urge the Company to consider. Based on unsolicited feedback received from other stakeholders and the market's reaction to the proposed merger, we can state with confidence that our views are widely held, " noted Flat Footed.

08:23 EDT SOBRsafe, TerraTech complete rollout of SOBRcheck to 16 facilities - SOBR Safe announced that oil and gas customer TerraTech Services has completed the rollout of SOBRcheck to of all of its 16 facilities across 11 states, for both fleet and workplace applications. TerraTech has now integrated SOBRcheck passive alcohol screening into its core safety protocols - each of its approximately 300 service center employees scan up to four times a day to continually verify alcohol fitness for duty.

08:19 EDT CCL Industries announces TSX acceptance of normal course issuer bid - CCL Industries announced that the Toronto Stock Exchange has accepted a notice filed by the Company to commence a normal course issuer bid. Under the Bid, the Company is authorized to acquire up to 14,500,000 of its Class B non-voting shares, being approximately 9.94% of the public float of the Class B non-voting shares as of May 15, 2023. No Bid is proposed to be made for the Company's Class A voting shares. All purchases will be made through the facilities of and in accordance with the rules of the TSX and all shares purchased will be cancelled. Except where reliance is placed on the TSX's block purchase exemption, the maximum number of shares that could be purchased under the Bid on any trading day will be limited to 64,005 Class B non-voting shares. The average daily trading volume for the six-month period ended April 30, 2023, was 256,023 Class B non-voting shares. The Bid will commence on May 25, 2023, and end no later than May 24, 2024. CCL's management believe that such purchases are an appropriate and desirable use of available funds. Pursuant to a previous notice of intention to conduct a normal course issuer bid, under which Company sought and received approval from the TSX to purchase up to 14,500,000 Class B non-voting shares for the period of May 25, 2022 to May 24, 2023, the Company has purchased, as of May 15, 2023, 1,224,447 Class B non-voting shares on the open market at an average purchase price of $60.06 per share. As of May 15, 2023, the issued and outstanding number of Class B non-voting shares was 165,728,767 and the public float of the Class B non-voting shares was 145,924,421. Purchases were made through the facilities of the TSX and all shares purchased were cancelled.

08:17 EDT Celularity announces $45M purchase order for its biomaterial products - Celularity announced that it has received a $45M purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store. Dr. Walid Swelim will serve as marketing manager for promotion and distribution of the products. This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity's global market strategy. "We are delighted today to announce receipt of a $45 million purchase order for private label Celularity Halal-Certified biomaterial products from Jamjoom. We are grateful to Jamjoom and to our exclusive territories distributor in the Islamic Markets, CH Trading Group, for making this important milestone possible," said Robert Hariri, M.D., Ph.D., Celularity's CEO, Chairman and Founder. "Our global expansion strategy and entrance into enter lucrative markets like the Middle East are enabled by our investment in platform technologies and infrastructure, including our world class cGMP/cGTP-compliant manufacturing facility in Florham Park, New Jersey, which allows us to rapidly scale and efficiently manufacture our proprietary placenta-derived, Halal-certified biomaterial products."

08:15 EDT CSW Industrials names Huerta as VP of Investor Relations, Treasurer - CSW Industrials (CSWI) announced it has named Alexa Huerta as Vice President, VP, Investor Relations and Treasurer. Huerta was most recently Senior Director of Investor Relations at Orthofix Medical (OFIX), a publicly traded company based in Lewisville, Texas, where she served in roles of increasing responsibility for 11 years.

08:14 EDT Ocean Biomedical announces patent award for novel cancer treatment - Ocean Biomedical announced that its Scientific Co-founder, Dr. Jack Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing immune system suppression by binding chitinase 3-like-1 polypeptides with Ocean Biomedical's proprietary immunoglobulin antibody. This process has been shown to suppress primary and metastatic tumor growth in multiple animal models and has potential use in multiple forms of visceral cancers. "We are excited to see Dr. Elias' work receive this important patent, and we are working on the systematic steps needed to progress the anti-CHi3L1 antibodies into the clinic to potentially become impactful new cancer therapeutics," commented Ocean Biomedical's CEO, Elizabeth Ng.

08:13 EDT Monogram Orthopaedics selects RTI Connext for remote surgery - Real-Time Innovations announced Monogram Orthopaedics has selected RTI Connext Anywhere to provide real-time connectivity during its fully remote simulated robotic surgery. Monogram recently achieved a significant industry milestone by completing the world's first fully remote, robotically-assisted Total Knee Arthroplasty procedure on a cadaver leg, where surgeons in New York City controlled an orthopedic robot located in Austin, Texas. Monogram uses Connext Anywhere to achieve reliable and low-latency communications for telesurgery, enabling highly precise and time-saving procedures. "A joint-replacement surgery is incredibly invasive, stressful and is still a largely manual process today, with 100,000 knee replacements failing each year," said Kamran Shamaei, CTO at Monogram Orthopaedics. "We feel strongly that our total knee replacement system, with RTI's underlying technology, will help to dramatically reduce this number, allowing patients to have a more stable, better-fitting knee replacement with fewer complications in a fraction of the time it takes today."

08:12 EDT Worksport factory closer to completion - Worksport announces that the completion of the Company's 222,000 sq. ft. Western N.Y manufacturing facility in New York is one step closer to starting production as the first materials are received at the factory. With the completion of Worksport's factory on the horizon, the Company can shift focus to sales and sustainable revenue growth. Once fully operational, the facility is anticipated to empower Worksport to realize its true potential, enable Worksport's manufacturing team to scale up production, enhance operational efficiency, and meet the increasing market demand for its products. Steven Rossi, Worksport CEO, stated "With the imminent completion of our state-of-the-art factory, we are now better positioned than ever to deliver outstanding products and generate substantial revenues. We have received many of the first materials required to start production."

08:10 EDT Southern California Bancorp appoints Martin to board of directors - Southern California Bancorp announces the appointment of Richard Martin to the Board of Directors of the Company and of its wholly owned subsidiary, Bank of Southern California, N.A., effective May 18, 2023. Martin has been appointed to serve on the Company's Audit and Risk Committee.

08:09 EDT QSAM Biosciences expands its study of CycloSam in treatment of bone cancer - QSAM Biosciences announces the addition of the Insight Research Institute at the Insight Hospital and Medical Center in Chicago, IL, as a clinical trial site approved to begin enrolling participants into the Phase 1 study evaluating CycloSam in patients with multiple types of bone cancer that either originated in or has metastasized to the bone. "We are pleased to be working with the excellent team at Insight Hospital and Medical Center to continue the expansion of our drug development program for CycloSam(R) in the large population center of Chicago," stated Douglas R. Baum, CEO and co-founder of QSAM. "We expect the addition of this fourth clinical trial site will help advance our study, and it also constitutes the initial site that will be serviced through our recently announced partnership with the leading nuclear pharmacy network, Radioisotope Life Sciences, RLS."

08:08 EDT T2 Biosystems sees 2023 sepsis, related product revenue $11M-$13M - The Company reiterates its full year 2023 financial outlook and continues to expect total sepsis and related product revenue of $11.0 million to $13.0 million, representing growth of 31% to 55%, compared to $8.4 million in 2022. Given the focus on product revenue, the Company is not providing guidance on research and contribution revenue.

08:07 EDT 51Talk Online Education to transfer listing to NYSE American from NYSE - 51Talk Online Education Group announced that it will transfer the listing of its American Depositary Shares from the New York Stock Exchange to NYSE American. The company has received the approval for listing from the NYSE American on May 22. In connection with the transfer, the company will voluntarily delist from the New York Stock Exchange, and will continue to trade on the NYSE until the delisting is complete. The company expects to begin trading on the NYSE American on or about May 26 under its current ticker symbol of "COE."

08:05 EDT TransUnion signs agreement with Constellation to purchase renewable energy - TransUnion (TRU) announced an 8.5 megawatt agreement with Constellation (CEG) to purchase renewable energy equivalent to the annual electricity use of its Chicago headquarters, which will also reduce TransUnion's emissions associated with purchased electricity. Through a 12-year agreement beginning in April 2025, TransUnion will purchase energy and renewable energy certificates generated by Swift Current Energy's Double Black Diamond Solar Project in downstate Illinois. Peak construction of the solar project began in March 2023. TransUnion's contract for the energy will begin in 2025. "The climate crisis remains a key global issue, and corporations must address the risks associated with the crisis with swift and purposeful action," said Chris Cartwright, President and CEO, TransUnion. "TransUnion is committed to continuing to assess, identify and, where feasible, implement options to integrate environmental sustainability into our global business, and procuring renewable energy is an important step toward realizing our enterprise climate strategy."

08:05 EDT T2 Biosystems announces 510(k) submission for T2Biothreat Panel - T2 Biosystems has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for the Company's T2Biothreat Panel. The FDA submission follows the recently completed U.S. clinical evaluation that demonstrated very high sensitivity and specificity, and included 350 contrived positive samples and over 470 negative blood samples from both healthy and febrile subjects. The T2Biothreat Panel is a fully-automated, direct-from-blood test designed to run on the FDA-cleared T2Dx Instrument and simultaneously detects six biothreat pathogens identified as threats by the U.S. Centers for Disease Control and Prevention, including the organisms that cause anthrax, tularemia, glanders, melioidosis, plague, and typhus. Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.

08:04 EDT Booz Allen awarded $919M contract to support warfighter capabilities - Booz Allen Hamilton announced it was awarded a performance-based task order, EDITS or Engineering, Development, Integration, and Technology-based Solutions, a research and development contract valued at $919M. EDITS is designed to enable the Soldier as a System concept and continuously enhance the warfighter's ability in all climatic conditions and combat situations, ensuring protection and survivability across multiple Department of Defense agencies. The task order supports the following mission partners: U.S. Army Program Executive Offices to include Soldier, elements of U.S. Special Operations Command , U.S. Army Development Command Soldier Center and the DOD's Joint Personnel Recovery Agency. This contract will enable Booz Allen to offer cutting-edge, technology-based solutions across services to meet emerging threats and ensure a versatile, expeditionary, agile, sustainable, and interoperable military capable of meeting and overcoming any challenge.

08:04 EDT 89bio initiates Phase 3 ENTRUST trial of pegozafermin - 89bio announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety and tolerability of pegozafermin in patients with severe hypertriglyceridemia. "We are pleased to initiate the ENTRUST trial of pegozafermin in SHTG, an important milestone for the company that demonstrates the rapid progress we have made since inception, and also signifies entry of the first FGF21 analog into Phase 3 development," said Hank Mansbach, Chief Medical Officer of 89bio. "We believe results from our previous trials in SHTG suggest a potentially favorable risk/benefit profile for pegozafermin as demonstrated through robust reductions in triglycerides, broad metabolic improvements including reductions in liver fat, as well as favorable safety and tolerability. We remain encouraged by pegozafermin's unique and differentiated profile relative to existing therapies and those in development to treat SHTG. Additionally, we believe there are opportunities for development synergies within our pegozafermin program and plan to leverage the safety database from the SHTG Phase 3 program to optimize clinical advancement in non-alcoholic steatohepatitis."

08:03 EDT Quantum Computing receives follow-on award for NASA climate change monitoring - Quantum Computing received a follow-on task order to its subcontract award to support NASA in remote sensing and climate change monitoring. In addition to testing its proprietary quantum photonic system for remote sensing applications, QCI will also be processing satellite images by utilizing its photonic-based reservoir computing technology. This initial testing engagement is expected to be completed during Q2. QCI, through its wholly owned subsidiary, QI Solutions, which focuses on federal government projects, will perform both the original quantum LiDAR work as well as applying photonic computing capability to process the LiDAR data. Upon successful completion of the task under the new subcontract, follow-on options include airborne testing and positioning these devices together with the photonic reservoir system to enhance the signal integrity of the satellite images to create a network for monitoring snow levels globally.

08:02 EDT T2 Biosystems announces exploration of strategic alternatives - T2 Biosystems has initiated a process to explore a range of strategic alternatives focused on maximizing value. To support the strategic process, the Company has initiated a restructuring plan which includes a reduction in force. The Company has engaged an advisory firm to explore all potential strategic alternatives to maximize value, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing, and other strategic transactions. No updates on the process are expected to be provided during the evaluation period unless and until the Board of Directors has concluded that disclosure is appropriate or required.

07:50 EDT Rubicon Organics announces 2023 key priorities - The company said, "Rubicon Organics has set out four key priorities for 2023: 1. Optimize Yield and Cultivation at our Delta Facility: Our priority is delivering super-premium quality cannabis flower products in the Canadian market. Producing at scale in a greenhouse environment is subject to seasonal impacts and commercializing new strains to meet the demand in market and our brand standards can present challenges. We remain focused on ongoing refinement and optimization in our cultivation systems. In 2022 the Company achieved several crops exceeding our nameplate 11,000 kg's capacity, and we expect 2023 to be a year of steady and consistent quality production. Additional tables will be installed in our facility to improve air circulation and increase capacity in the second half of 2023, with standard maintenance scheduled during downtime. 2. Maximize Canadian Premium Opportunity: Rubicon is focused on maximizing the gross margin we earn from each gram produced from our Delta Facility. Delivering both the right genetics and product formats to the customer at the right price to value ratio and maintaining good relationships with the provincial distributors and retail stores are critical to our success. In 2023 we are driving to grow our Simply Bare Organic brand and to premiumize opportunistically elements of our 1964 Supply Co brand the impact of both would be positive on our gross profit. As we have forecast demand beyond our available supply from our Delta Facility we have begun projects that we expect to incrementally grow our net revenue and gross profit. We intend to launch products that do not require the Delta Facility's capacity that we anticipate will add incremental gross profit to our results in a cost effective and efficient manner such as through contract grow relationships which will be to Rubicon's quality standards. We are also actively looking to build our revenue with the launch of new products under our existing brands which can be contracted to other licensed producers thus not utilizing our existing capacity. We intend to deliver this incremental gross profit without significant incremental overhead cost to our business, thus driving additional overall profitability. 3. Drive Efficiency in Processes and Systems: As steady state has been established at our Delta Facility, we now are seeking to create efficiency in our systems away from manual processes or those where there is reliance on key individuals to increase the resilience and repeatability of our systems and reduce cost. As part of this process, Rubicon is evaluating new information systems and expects to begin implementing new systems beginning in the second half of 2023. This project will increase costs in the short-term, but we believe will improve efficiency of the existing business and ready Rubicon for further growth. 4. Build a Proud, Engaged Team Delivering Outstanding Results: With turmoil in the cannabis sector in the last number of years, coupled with the stresses relating to work in the pandemic and tightness of the labour market, we have seen considerable turnover in the business. We believe that in order to deliver a premium product to market, our team members being engaged and proud is important to put our best foot forward with our consumers and customers. Furthermore, the cost and resources used when there is labour turnover can be considerable. As part of achieving an engaged and proud team, we have set clear goals and objectives linked to reward to recognize the hard work and accomplishments of team members. We also have begun reviewing our Company values listening to our people as part of the process and Rubicon's evolution now that we are in a more steady state.Rubicon believes that our cannabis quality, brand positionings and product offerings will drive continued growth in net revenue, resulting in an increase in gross profit and Adjusted EBITDA for the full year 2023. With a stable cost base, this anticipated growth in net revenue and gross profit would improve our operating leverage. Additionally, we expect to achieve positive cashflow for the full year, pending opportunistic investment decisions. As a business we are now looking to increase the volume of product that we have available for sale to fill the demand we have for our quality products. The business is evaluating several options to increase our capacity. We believe that despite any market volatility, inflationary pressures, regulatory change, our product quality and brand portfolio has positioned Rubicon to win in the premium cannabis market."

07:46 EDT CalciMedica appoints Jaeger as CRO, Cunningham as SVP of Clinical Development - CalciMedica (CALC) announced the appointments of Raven Jaeger, M.S., as Chief Regulatory Officer, CRO, and Andrew Cunningham, M.D., MRCPI, as Senior Vice President, SVP, of Clinical Development. Both Jaeger and Dr. Cunningham bring extensive expertise to their positions on the CalciMedica team. Most recently, Jaeger served as the Chief Regulatory Officer at Diffusion Pharmaceuticals (DFFN). Prior to this position, Dr. Cunningham served as a consultant for CalciMedica since December 2022.

07:44 EDT Quipt Home Medical on preliminary list to join Russell 2000, 3000 indexes - Quipt Home Medical announces it is on a preliminary list dated May 19, 2023 issued by FTSE Russell to join the Russell 2000 and 3000 Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. Updates are provided by the Russell Microcap Index on May 26, June 2, June 9, June 16 and June 23. "Being included in the Russell 2000(R) and 3000(R) Indexes would be an affirmation of our strategic journey and a testament to the relentless efforts of our team. We remain committed to delivering sustained value to our shareholders and are thrilled by the idea of being included with some of the most forward-thinking companies in the United States, which we believe would considerably increase our visibility and access to the worldwide investment community," commented Greg Crawford, CEO and Chairman of Quipt. "This inclusion would truly reflect the substantial growth experienced by our company and our evolution as a publicly traded company over the last several years. We are extremely well positioned to continue executing on our growth strategy, which has yielded robust and consistent financial performance, and we look forward to providing our shareholders with updates as we progress on our future vision."

07:43 EDT Aclarion announces Karahalios will advise as a KOL - Aclarion announced that Dean Karahalios, M.D., Medical Director of Brain & Spine Institute at Advocate Aurora Health Care in Illinois, will advise the company as a key opinion leader, KOL nationally.

07:42 EDT Empire State Realty Trust announces Flagstar assumes lease at 1400 Broadway - Empire State Realty Trust announced that Flagstar Bank, has assumed the entire 313,109 square foot lease at 1400 Broadway, formerly leased by Signature Bank, under the same terms through 2039 with the exception of an approximate $3 per square foot rent reduction for the first five years of the lease amendment, which equates to an approximate 1.5% rent reduction over the duration of the lease. In the second quarter of 2023, ESRT will reverse $5.8M of the $6.4M straight-line reserve taken in the first quarter of 2023. These adjustments will have a combined estimated 2c per share impact on 2023 annual Funds from Operations . This and any other updates to FFO guidance will be provided when the Company reports its second quarter 2023 earnings.

07:37 EDT Arrowhead presents interim data from ARO-ANG3 study for HoFH treatment - Arrowhead Pharmaceuticals presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company's investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3, in patients with homozygous familial hypercholesterolemia HoFH . The company is currently planning a Phase 3 study to further investigate ARO-ANG3 and intends to conduct a meeting with regulatory authorities in the second half of 2023 to discuss the proposed study design. The data were presented at the 91st European Atherosclerosis Society Congress in a poster titled, "ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum LDL-Cholesterol, Apolipoprotein B, and Angiopoietin-like Protein 3 in Patients with Homozygous Familial Hypercholesterolaemia," which may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

07:36 EDT Bioventus completes divestiture of wound business - Bioventus completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction, announced earlier this month, enables Bioventus' improved focus on execution and delivers approximately $30 million of net closing proceeds, which will be used for debt repayment. In connection with the closing of the sale, Bioventus and LifeNet Health have also entered into a Sales Agent Agreement under which LifeNet Health will have exclusive rights to sell SonicOne ultrasonic wound debridement products in the US and Canada.

07:36 EDT Monte Rosa Therapeutics announces second development candidate MRT-6160 - Monte Rosa Therapeutics announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader of VAV1. The Company plans to file an Investigational New Drug application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases. "Our goal centers on pioneering therapeutically meaningful new drugs for patients with serious diseases. By addressing VAV1, a validated but previously undruggable target, we believe we've created a potentially groundbreaking therapy for patients suffering from a range of serious autoimmune conditions, particularly those involving both T- and B cell-mediated autoimmunity," said Markus Warmuth, M.D., CEO of Monte Rosa. "MRT-6160 is expected to be our second MGD to enter clinical trials, showcasing the continued productivity of our QuEEN(TM) platform. We anticipate significant progress and milestones in our portfolio in the upcoming year, including initial clinical data from our GSPT1 MGD, MRT-2359, in the second half of this year and filing of an IND application for MRT-6160 in the first half of next year."

07:34 EDT CohBar, Morphogenesis enter definitive all-stock merger agreement - CohBar and Morphogenesis announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market. The transaction is expected to close in the third quarter of 2023. Morphogenesis' technologies, which can be used to target large unmet medical needs across a variety of cancers, include: Immune Fx Personalized Cancer Vaccines: IFx is designed to prime and activate an innate immune response against patient-specific tumor antigens, overcoming primary resistance to checkpoint inhibitors. Morphogenesis is currently preparing for a single Phase 2/3 registration trial of its lead personalized cancer vaccine, IFx-Hu2.0, as an adjunct to Keytruda in first line treatment for advanced Merkel Cell Carcinoma. This study is expected to be conducted under a Special Protocol Assessment agreement with the FDA and to commence in early 2024. Additionally, Morphogenesis is advancing IFx-Hu3.0, its mRNA vaccine, toward IND-enabling studies in 2024 for the treatment of aggressive diffuse large B-cell lymphoma. Tumor Microenvironment Modulators: TME Modulators are designed to address one of the primary causes of acquired resistance to immunotherapies, including checkpoint inhibitors or cellular therapies like CAR-T. Leveraging its new class of novel bi-functional antibody drug conjugates, Morphogenesis is targeting a recently identified delta receptor on myeloid derived suppressor cells. MDSCs comprise a major component of cells in the tumor microenvironment and are responsible for suppressing the immune system's attack against the tumor. Morphogenesis is constructing several MDSC targeted, bi-functional ADCs for in vitro and in vivo characterization, targeting lead selection by the end of 2024. Under the terms of the merger agreement, subject to stockholder approval, each holder of CohBar common stock as of immediately prior to the closing of the transaction will be issued a dividend equal to approximately 3.30 shares of CohBar common stock on or about the effective date of the merger. On a pro forma basis taking into account the concurrent financing described below and the issuance of the stock dividend, pre-merger CohBar equityholders are expected to collectively own approximately 15% and pre-merger Morphogenesis equityholders are expected to collectively own approximately 77%, respectively, of the common stock of CohBar on a pro forma basis. Upon execution of the merger agreement, CohBar also entered into a stock purchase agreement with an affiliate of an existing investor in Morphogenesis for a $15 million private placement that is expected to close concurrently with the closing of the proposed merger. The proceeds from the private placement will be used to fund the advancement of the combined company's immunotherapy-focused development pipeline, with an anticipated cash runway through 2024. Immediately following the closing of the merger and the closing of the private placement, the shares issued in the private placement are anticipated to represent approximately 9% of the common stock of CohBar on a pro forma basis. Additionally, pre-merger CohBar stockholders and certain warrant holders of record will receive a contingent value right. Holders of the CVR will be entitled to receive certain payments from proceeds received by CohBar, if any, related to the disposition of CohBar's legacy mitochondrial assets for a period of three years following the closing of the proposed merger. The merger agreement has been approved by the boards of directors of both companies and is subject to stockholder approval of both companies and other customary closing conditions. The proposed merger is expected to close in the third quarter of 2023. Following the merger, the combined company will be headquartered in Tampa, Florida, and the executive officers are expected to be James Bianco, MD as Chief Executive Officer, and Dan Dearborn, CPA as Chief Financial Officer. The merger agreement provides that the board of directors of the combined company will be composed of seven members, with five members initially designated by Morphogenesis and two members initially designated by CohBar.

07:30 EDT ParkerVision files complaints against Texas Instruments, NXP Semiconductors - ParkerVision (PRKR) filed complaints in the Western District of Texas against Texas Instruments (TXN) and NXP Semiconductors (NXPI), for the infringement of four of its U.S. patents. The complaints request jury trials to determine, among other items, the financial damages for the unauthorized use of ParkerVision's wireless patented technologies in semiconductor chips used in automotive wireless applications, wireless infrastructure, and numerous other devices incorporating WiFi and Bluetooth wireless connectivity.

07:21 EDT Lordstown Motors takes actions to reduce costs, preserve liquidity - The company said, "Since start of commercial production, the Company has completed 56 Endurance vehicles and delivered 18 to customers, 12 since resuming deliveries in late April. The Endurance continues to improve with each software update, and our team is encouraged by the most recent customer feedback. In light of the Foxconn dispute and the uncertainty regarding whether or to what extent Foxconn will fulfill its funding obligations under the Investment Agreement, the Company has taken aggressive actions to reduce costs and preserve liquidity. As of April 30, 2023, the Company had cash, cash equivalents and short-term investments of approximately $165 million, a decrease of approximately $11 million from the quarter ended March 31, 2023."

07:17 EDT Lordstown Motors announces 1-for-15 reverse stock split - Lordstown Motors will effect a 1:15 reverse stock split of its Class A common stock, $0.0001 par value per share, that will become effective at 12:01 a.m. Eastern Time on May 24, 2023. Lordstown Motors' Class A common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market, under its existing symbol, "RIDE", when the market opens on May 24, 2023. The new CUSIP number for the Company's Class A common stock will now be 54405Q 209. The Reverse Stock Split was approved by the Company's stockholders at its 2023 Annual Meeting of Stockholders, held on May 22, 2023, with the final ratio determined by the Company's board of directors. The Company has filed an amendment to its Second Amended and Restated Certificate of Incorporation, as amended, to effect the Reverse Stock Split as of the Effective Time. The Reverse Stock Split is intended to improve the marketability and liquidity of the Class A common stock. A higher market price can make the Class A common stock more attractive to a broader range of institutional investors, professional investors, and other members of the investing public. In addition, the Reverse Stock Split is intended to increase the per share market price of the Class A common stock in order to satisfy Nasdaq's $1.00 minimum bid price requirement.

07:14 EDT Dick's Sporting backs FY23 CapEx view $670M-$720M on gross basis - Backs FY23 CapEx view $550M-$600M on a net basis.

07:12 EDT Protalix to join Russell 3000 Index - Protalix announced that it is set to join the Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, according to a preliminary list of additions posted May 19.

07:11 EDT Emerita announces drill results from program La Romanera, La Infanta deposits - Emerita Resources announce the maiden independent NI 43-101 compliant resource estimate based on drill results from the 2022-23 resource delineation drilling program at La Romanera and La Infanta deposits, part of Emerita's wholly owned Iberian Belt West project, IBW. David Gower, P.Geo., CEO of Emerita stated, "The last 12 months have been a busy and exciting time for the Spain based Emerita exploration team. It is a credit of the team to be able to release our first NI 43-101 compliant resource estimate for the IBW project in a compressed time frame given drilling commenced on La Romanera only last summer. This represents an interim mineral resource estimate as work continues to expand the resources at IBW. The recent exploration mapping, drilling and geophysical surveys demonstrate both La Romanera and La Infanta remain open along strike and at depth. This coupled with targets associated with the recently expanded land position provides a lot of additional targets for new discoveries. Metallurgical test work is commencing which will inform a key component of a future economic study of IBW while we continue to explore."

07:10 EDT FORME joins Webull Corporate Communications Platform - Interactive Strength Inc. d/b/a FORME announced that it has joined the new Webull Corporate Communications Service Platform. Interactive Strength Inc. d/b/a FORME completed its IPO on May 2, 2023 and is now listed on Nasdaq under "TRNR." The Interactive Strength Inc. d/b/a FORME portal on the Webull platform will help provide the Company with a direct line of communication with its retail shareholders while providing Interactive Strength Inc. d/b/a FORME's followers with timely notifications regarding corporate content like company news, earnings reports, investor presentations, and more.

07:10 EDT Nuvista Energy says production impact from wildfires averaged 35,000 boe/d - NuVista Energy provides an update on the ongoing wildfire situation in the Grande Prairie area. The company said, "As previously advised, several of our fields were shut in on May 5th as a precautionary measure to ensure the protection of our people, the public, and our assets in the vicinity of the wildfires. In addition, our third party midstream partners have had to do the same, with the collective status changing frequently through the period since May 5th. Fires have remained in the range of 5-10 km away but with access roads blocked, personnel have been monitoring from safe locations. Winds and humidity have been more favorable in the last few days, and meaningful rainfall has reached the area, which is hoped to help stabilize the situation. The temporary production impact has averaged approximately 35,000 Boe/d from May 5 - 22. With more favorable winds and weather, we were able to restart most operations over the prior weekend, with daily production currently increased to approximately 65,000 Boe/d. If rain and favorable winds occur as forecast, we expect to restore full production levels of approximately 80,000 Boe/d or more as soon as the situation stabilizes fully. We will provide quarterly production guidance at that time. We are not aware of material damage to any company or third party assets and infrastructure in the area. We thank our field staff, our midstream partners, and the local fire authorities for their swift and professional response to this situation, and our thoughts remain with any impacted community members."

07:08 EDT Tiziana Life Sciences participates in Webull Corporate Communication platform - Tiziana Life Sciences announced that they are now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing Tiziana's followers with instant notifications regarding corporate content like company news, earnings reports, investor presentations, and more.

07:07 EDT Rocket Pharmaceuticals gets RMAT designation for RP-L301 gene therapy for PKD - Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy or RMAT, designation to RP-L301, the Company's investigational lentiviral-based gene therapy for Pyruvate Kinase Deficiency, PKD , a rare blood disorder characterized by severe anemia and excessive red blood cell breakdown. RMAT designation was granted based on robust safety and efficacy data from the ongoing Phase 1 RP-L301 clinical trial and its potential to cure a life-threatening disease for which no curative therapies currently exist. The designation will provide the benefits of added FDA guidance and expedited review through the program's development. "Receiving RMAT designation from the FDA for RP-L301 is a major achievement in our pursuit to bring the first, potentially curative gene therapy treatment to patients living with PKD who have high unmet need. Notably, PKD has an estimated prevalence of up to 8,000 patients in the U.S. and Europe and represents one of the most significant patient opportunities in our LV hematology portfolio," said Kinnari Patel, PharmD, MBA, President and Chief Operating Officer, Rocket Pharma. "Further, all four Rocket-sponsored programs with clinical data now have received RMAT designation from the FDA across both platforms, a unique showcase of our team's ability both to select appropriate targets and develop gene therapies for them." ...The first pediatric patient results suggest efficacy similar to the adult cohort with an initial greater than five-point increase in hemoglobin . The infusion was well tolerated, with engraftment achieved at day +15, hospital discharge less than one month following infusion, and no RP-L301-related serious adverse events or red blood cell transfusion requirements following engraftment.

07:06 EDT Shutterstock to acquire GIPHY from Meta Platforms for $53M - Shutterstock (SSTK) announced that it entered into a definitive agreement to acquire GIPHY from Meta Platforms (META). GIPHY is the world's largest collection of GIFs and stickers that supplies casual conversational content. Financial Highlights: Consideration for the transaction consists of $53M of net cash paid at closing, inclusive of working capital. Cash consideration funded through cash-on-hand and existing revolving credit facility. In connection with this transaction, GIPHY's current owner, Meta Platforms, is entering into an API agreement to ensure continued access to GIPHY's content across Meta's platform. Shutterstock is maintaining its 2023 revenue and adjusted EBITDA margin guidance. GIPHY is expected to add minimal revenue in 2023 with focused monetization efforts taking place over the course of 2024. The transaction is targeted to close in June 2023, subject to customary closing conditions.

07:05 EDT mCloud Technologies provides update from committee on strategic alternatives - mCloud Technologies provided an update on the company's exploration of currently active strategic alternatives. On March 29, mCloud formed a special committee comprising independent members of mCloud's Board of Directors for the purposes of exploring strategic alternatives to maximize shareholder value. Over the past several weeks, the Special Committee has narrowed its efforts toward a transaction that would result in the acquisition of the company by a strategic partner. The company is continuing to pursue this potential transaction but is currently unable to provide any further guidance on the nature or timing of the proposed transaction.

07:04 EDT Agrify releases PurePacks double filtration rosin bags - Agrify Corporation announced the release of PurePacks, seamless, double filtration rosin bags, under solventless extraction brand PurePressure.PurePacks are premium, double-layer rosin filter bags used with rosin presses for heat pressure filtration. As PurePressure's third rosin bag release, PurePacks are the result of years of research and development in response to customer feedback. PurePacks are available in five different sizes ranging from 2"x3" to 2.5"x9" and are sold in packs of 25, 100, or 200 on the PurePressure website. Prices start at $45/pack.

07:03 EDT Tonix Pharmaceuticals announces the isolation, characterization of TNX-4300 - Tonix Pharmaceuticals announced the isolation and functional characterization of the two mirror image isomers of racemic tianeptine, which is marketed outside the U.S. as a treatment for major depressive disorder, MDD. Tonix scientists discovered that the (S)-isomer of tianeptine activates PPAR-beta/delta, restores neuroplasticity in neuronal tissue culture and is free of micro-opioid receptor activity. In contrast, (R)-tianeptine activates the micro-opioid receptor and lacks PPAR-beta/delta activity. Based on these discoveries, Tonix has begun preclinical development of the (S)-isomer, TNX-4300, as a treatment for MDD, bipolar disorder, Alzheimer's disease, and Parkinson's disease. Tonix is planning to submit data supporting tianeptine's mechanism of action for presentation at upcoming scientific conferences and for publication in peer reviewed journals. "The tianeptine marketed outside the U.S. for treating depression is a 1:1 racemic mixture of two mirror image isomers," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "The discovery reported today is that the (S)-isomer is responsible for tianeptine's activity on PPAR-beta/delta and restoring neuroplasticity, and the (R)-isomer for its off-target activity on the micro-opioid receptor. Our team of scientists isolated and characterized the (S)-isomer, that is now TNX-4300 and under development for psychiatric and neurological diseases." Dr. Lederman continued, "Our ongoing work on racemic tianeptine in depression is expected to inform and potentially accelerate the development of TNX-4300. Although the dose of tianeptine for treating depression is well-established from racemic studies, the dose range for treating neurological diseases is not yet determined. Because TNX-4300 lacks the micro-opioid receptor activity, we believe such effects will not limit the dosing of the (S)-tianeptine for these other indications."

07:02 EDT Zentalis to host investor call on results for azenosertib monotherapy - Zentalis Pharmaceuticals announced that the Company will host an investor update call to share the safety and efficacy results from its ongoing monotherapy dose optimization Phase 1 study of azenosertib, its potentially first-in-class WEE1 inhibitor product candidate. The Company will also recap data that will be presented at the 2023 American Society of Clinical Oncology Annual Meeting and provide an overview of future clinical development plans for azenosertib. The webcast will be at 8:00 a.m. ET on Tuesday, June 6, 2023

06:59 EDT Brookfield Corp. renews normal course issuer bid - Brookfield has received approval from the Toronto Stock Exchange for the renewal of its normal course issuer bid to purchase up to 142,042,619 Class A Limited Voting Shares, representing 10% of the public float of Brookfield's outstanding Class A Shares. The period of the normal course issuer bid will extend from May 25, 2023 to May 24, 2024, or an earlier date should Brookfield complete its purchases. Of the 138,664,974 Class A Shares approved for purchase under Brookfield's prior normal course issuer bid that commenced on May 25, 2022 and will expire on May 24, 2023, Brookfield purchased 18,216,408 Class A Shares as of May 17, 2023; 4,958,290 Class A Shares through open market purchases on the TSX and 13,258,118 Class A Shares through open market purchases on the NYSE as of May 17, 2023. Brookfield intends to enter into an automatic purchase plan on or about the week of June 19, 2023 in relation to the normal course issuer bid.

06:57 EDT AutoZone reports inventory up 7.4% y/y - The company's inventory increased 7.4% over the same period last year, driven by inflation and its growth initiatives. Net inventory, defined as merchandise inventories less accounts payable, on a per store basis, was negative $215,000 versus negative $216,000 last year and negative $227,000 last quarter. During the quarter ended May 6, 2023, AutoZone opened 22 new stores in the U.S., six in Mexico and two in Brazil. As of May 6, 2023, the company had 6,248 stores in the U.S., 713 in Mexico and 83 in Brazil for a total store count of 7,044.

06:20 EDT Affimed receives IND clearance for Phase 2 trial of AFM13, AB-101 combination - Affimed announced that the FDA has cleared its IND application for the combination of AFM13, its first-in-class tetravalent bispecific innate cell engager - ICE - and AB-101, Artiva Biotherapeutics' clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived natural killer cells to initiate the clinical trial, AFM13-203. The study will evaluate the safety and efficacy of AFM13 in combination with AB-101 in patients with r/r cHL and CD30-positive peripheral T-cell lymphoma. Affimed intends to initiate the study in 3Q23 and expects to report data from the safety run-in phase in the first half of 2024. AFM13-203 will build on data generated from the company's AFM13-104 study together with The University of Texas MD Anderson Cancer Center, which demonstrated the promise of AFM13 in combination with cord blood-derived NK cells for the treatment of r/r cHL and Non-Hodgkin lymphoma patients. Data from the AFM13-104 study demonstrated a 94% ORR and a CR rate of 71% in 35 heavily pre-treated CD30-positive Hodgkin lymphoma and Non-Hodgkin lymphoma patients treated at the recommended Phase 2 dose. 63% of patients treated at the RP2D with at least 6 months of follow-up after the initial infusion remained in CR for at least 6 months. In addition, the treatment was well tolerated. During the IND process, Affimed requested FDA feedback on the suitability of the study to support an accelerated approval in cHL. At the recommendation of the FDA, in parallel to advancing the study, Affimed expects to have further discussions with the agency on the requirements for a registration application in the U.S.

06:04 EDT Achieve Life Sciences' cytisinicline shows smoking cessation benefit in trial - Achieve Life Sciences announced positive topline results from the Phase 3 ORCA-3 trial of cytisinicline for smoking cessation and nicotine dependence. Consistent with the previously reported Phase 3 ORCA-2 study, ORCA-3 showed a statistically significant benefit in helping people to quit smoking compared to placebo, with low rates of adverse events. The primary endpoint for ORCA-3 was biochemically verified smoking cessation measured during the last 4 weeks of treatment. Subjects who received 12 weeks of cytisinicline treatment had 4.4 times higher odds, or likelihood, to have quit smoking during the last 4 weeks of treatment compared to subjects who received placebo. The smoking cessation rate during weeks 9 through 12 was 30.3% for cytisinicline compared to 9.4% for placebo. The continuous smoking cessation rate from week 9 to week 24 was 20.5% for the 12-week cytisinicline arm compared to 4.2% for placebo. Similar to ORCA-2 findings, cytisinicline was well-tolerated with no treatment-related serious adverse events reported. The most commonly reported adverse events for placebo, 6-week cytisinicline, and 12-week cytisinicline were: insomnia, abnormal dreams, nausea and headache.

06:02 EDT Netflix appoints Arnold Schwarzenegger as 'chief action officer' - Netflix said in a statement on Monday: "Nobody knows action like Arnold Schwarzenegger. That's why we're excited to introduce Arnold as our new Chief Action Officer! So whether you want to catch Schwarzenegger's first-ever television role in FUBAR, Chris Hemsworth's highly anticipated return in Extraction 2, a new season of The Witcher with Henry Cavill or Gal Gadot as an intrepid heroine in Heart of Stone, Arnold is working around the clock to bring you the most explosive series and films on earth! Get ready for a hard-hitting roller coaster ride as Netflix cranks its action slate into the next gear." Reference Link

05:35 EDT Cummins to purchase two commercial vehicle manufacturing plants from Faurecia - Cummins announced it has entered into a definitive agreement with Faurecia, a company of the Forvia Group, to purchase two of Faurecia's commercial vehicle manufacturing plants and their related activities for EUR 142M. The manufacturing facilities are located in Columbus, Indiana and Roermond, Netherlands. The transaction, which is subject to customary closing conditions, receipt of applicable regulatory approvals in the United States, Germany and the Netherlands, and favorable completion of the consultation process with the works council and trade unions in Roermond, is expected to close by the end of the calendar year.

05:30 EDT Textron announces delivery of Cessna SkyCourier - Textron announced the recent delivery of the first passenger unit of the twin-engine, large-utility turboprop, the Cessna SkyCourier, for use by Western Aircraft, doing business in Hawaii as Lana'i Air. The company offers luxury air service connecting Oahu to the island of Lana'i.

05:07 EDT Vipshop CFO David Cui to resign, Mark Wang to succeed - The company also announced that it has appointed Mark Wang as its chief financial officer, effective May 24. Wang will succeed David Cui, who has decided to resign from this position for personal reasons. Prior to joining Vipshop, Wang served as the chief financial officer of Benlai Group, an online fresh grocery player in China, from April 2021 to November 2022.